What is the clinical evidence from this study?

Study design: Cohort. Population: perimembranous ventricular septal defect (pmVSD) (n=19). Intervention: Amplatzer Membranous VSD Occluder 2. Primary outcome: Successful device implants.

What does this research mean for the field?

Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer Membranous VSD Occluder 2 achieves a 95% implant success rate with no complete atrioventricular block at one-year follow-up. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

May 22, 2013Catheterization and Cardiovascular Interventions

Transcatheter closure of perimembranous ventricular septal defect with the Amplatzer® membranous VSD occluder 2: Initial world experience and one‐year follow‐up

View Full Paper

Ask AI

Bookmark

Key result

Transcatheter perimembranous VSD closure using Amplatzer Occluder 2 achieves 95% implant success without procedural complications.

n=19

Why the study?

Transcatheter closure of perimembranous ventricular septal defects has been associated with substantial risk of complete heart block, limiting its use.

Does transcatheter closure using the Amplatzer Membranous VSD Occluder 2 safely and effectively treat perimembranous ventricular septal defects without causing complete heart block?

Study Design

Type

Cohort (n=19)

Multicenter

Yes

Structured PICO

Does transcatheter closure using the Amplatzer Membranous VSD Occluder 2 safely and effectively treat perimembranous ventricular septal defects without causing complete heart block?

Population

19 patients (median age 6 years) with perimembranous ventricular septal defect undergoing catheter closure, followed for a mean of 14 months.

Exposure

Transcatheter closure using the Amplatzer Membranous VSD Occluder 2

Outcome

Procedural success, complications (specifically AV block), and residual shunting at mid-term follow-up (14 ± 3 months)safety

The Amplatzer Membranous VSD Occluder 2 appears feasible and safe for transcatheter closure of perimembranous VSDs, notably avoiding the complication of complete heart block in this initial cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May extend transcatheter options for perimembranous VSD; hypothesis-generating pending randomized evidence.

Cite This Study

Tzikas et al. (2013) conducted a cohort in perimembranous ventricular septal defect (pmVSD) (n=19). Amplatzer Membranous VSD Occluder 2 was evaluated on Successful device implants. Transcatheter closure of perimembranous ventricular septal defects using the Amplatzer Membranous VSD Occluder 2 achieved successful implantation in 95% of patients with no procedural complications.

synapsesocial.com/papers/6aaa4ea8274631fa87a8872a https://doi.org/10.1002/ccd.25004

View Full Paper

Ask AI

Bookmark

Transcatheter closure of perimembranous ventricular septal defect with the Amplatzer® membranous VSD occluder 2: Initial world experience and one‐year follow‐up

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Transcatheter closure of perimembranous ventricular septal defect with the Amplatzer® membranous VSD occluder 2: Initial world experience and one‐year follow‐up

Study Design

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider